Abstract
Estrogen receptors (ER) play important roles in the development and progression of breast and ovarian cancers. ERs mediate transcriptional regulation through interaction with cofactors and binding to response elements within the regulatory elements of target genes. Here, we examined the expression and function of TBLR1/TBL1XR1, a core component of NCoR (nuclear receptor corepressor) and SMRT (silencing mediator of retinoic acid and thyroid receptor) corepressor complexes, in breast and ovarian cancers. We found that although TBLR1 is present in both the nucleus and cytoplasm of normal and neoplastic breast and ovarian cells, it is expressed at significantly higher levels in the nucleus of malignant breast and ovarian cells compared to benign cells. TBLR1 functions as an ER corepressor to inhibit ER-mediated transcriptional activation in both breast and ovarian cell lines, but it has no effect on androgen receptor (AR) mediated transcriptional activation in these cells. Furthermore, ectopic expression of nuclear TBLR1 in breast and ovarian cancer cells stimulates cell proliferation. The increased cell proliferation by nuclear TBLR1 is through both ER-independent and ER-dependent mechanisms as evidenced by increased growth in hormone-free medium and estrogen medium, as well as reduced growth with ER knockdown by siRNA. Nuclear TBLR1 overexpression also increased migration and invasion in both breast and ovarian cancer cells. Determining the functional relationship between TBLR1 and ER may provide insights to develop novel treatment strategies and improve response to hormonal therapy in breast and ovarian cancers.
Original language | English (US) |
---|---|
Pages (from-to) | 2351-2360 |
Number of pages | 10 |
Journal | American Journal of Cancer Research |
Volume | 6 |
Issue number | 10 |
State | Published - 2016 |
Funding
This material is supported in part by the De-partment of Veterans Affairs, Veterans Health Administration, Office of Research and Development (Biomedical Laboratory Research and Development). The NYU Experimental Pa-thology Immunohistochemistry Core Labora-tory is supported in part by the Laura and Is-aac Perlmutter Cancer Center Support Grant (NIH/NCI P30CA016087) and the National Institutes of Health S10 Grants (NIH/ORIP S10OD01058 and S10OD018338).
Keywords
- Breast cancer
- Estrogen receptor
- Nuclear TBLR1
- Ovarian cancer
- TBL1XR1
ASJC Scopus subject areas
- Oncology
- Cancer Research